ИММУНОЛОГИЧЕСКИЕ МЕХАНИЗМЫ РАЗВИТИЯ ПРИОБРЕТЕННОЙ ТОКСИЧЕСКОЙ ГЕМОЛИТИЧЕСКОЙ АНЕМИИ В ЭКСПЕРИМЕНТЕ
##plugins.themes.bootstrap3.article.main##
Аннотация
##plugins.themes.bootstrap3.article.details##
Лицензионный договор на право использования научного произведения в научных журналах, учредителем которых является Пермский государственный национальный исследовательский университет
Текст Договора размещен на сайте Пермского государственного национального исследовательского университета http://www.psu.ru/, а также его можно получить по электронной почте в «Отделе научных периодических и продолжающихся изданий ПГНИУ»: YakshnaN@psu.ru или в редакциях научных журналов ПГНИУ.
Библиографические ссылки
Baier J. Е., Poehlau D. Is alpha-methyldopa-type autoimmune hemolytic anemia mediated by inter-feron-gamma? // Annals of Hematology. 1994. Nov. Vol. 69(5). P. 249-251.
Baker H.J., Lindsey J.R., Weisbroth S.H. The Laboratory Rat. New York: Academic Press, 1979. Vol. I: Biology and Disease. P. 55-57.
Berger J. Phenylhydrazine haematotoxicity // J. Appl. Biomed. 2007. Vol. 5. P. 125-130.
Betensky M. et al. Immune hemolytic anemia with drug-induced antibodies to carboplatin and vincristine in a pediatric patient with an optic pathway glioma // Transfusion. 2014. Vol. 54 (11) P. 2901-2905.
Bollotte A. et al. Drug-induced hemolytic anemia: A retrospective study of 10 cases // Rev. Med. Interne. 2014. Vol. 35(12). P. 779-789.
El-Ashmawy I.M., Gad S.B., Salama O.M. Grape seed extract prevents azathioprine toxicity in rats // Phytother. Res. 2010. Vol. 24(11). P. 1710-1715.
Exon J.H. et al. Effects of subchronic exposure of rats to 2-methoxyethanol or 2-butoxyethanol: thymic atrophy and immunotoxicity // Fundam. Appl. Toxicol. 1991. May. Vol. 16 (4). P. 830-840.
Garratty G. Drug-induced immune hemolytic anemia // ASH Education Book January. 2009. Vol. 1. P. 73-79.
Garratty G., Arndt P.A. An update on drug-induced immune hemolytic anemia // Immunohematology. 2007. Vol. 23(3). P. 105-119.
Ghanayem B.I., Sanchez I.M., Matthews H.B. Development of tolerance to 2-butoxyethanol-induced hemolytic anemia and studies to elucidate the underlying mechanisms // Toxicol. Appl. Pharmacol. 1992. Feb. Vol. 112 (2). P. 198-206.
Ghanayem B.I., Sullivan C.A. Assessment of the haemolytic activity of 2-butoxyethanol and its major metabolite, butoxyacetic acid, in various mammals including humans // Hum. Exp. Toxicol. 1993. Jul. Vol. 12 (4). P. 305-311.
Haddad H., Mohammad F., Dai Q. Bendamustine-induced immune hemolytic anemia in a chronic lymphocytic leukemia patient: A case report and review of the literature // Hematol. Oncol. Stem. Cell Ther. 2014. Dec. Vol. 7(4). P. 162-164.
Haley K.M. et al. Fatal carboplatin-induced immune hemolytic anemia in a child with a brain tumor // J. Blood Med. 2014. Vol. 15(5). P. 55-58.
Hillman R.S., Ault K.A., Rinder H.M. Hematology in Clinical Practice. 4th Ed. 2005. P. 135-151.
Hematology: basic principles and practice / R. Hoffman et al. 5th ed. 2008. P. 645-659.
Horn S., Bashan N., Gopas J. Phagocytosis of phenyl-hydrazine oxidized and G-6-PD-deficient red blood cells: the role of cell-bound immunoglobulins // Blood. 1991. Oct 1. Vol. 78 (7). P. 1818-1825.
Johnson S.T., Fueger J.T., Gottschall J.L. One center's experience: the serology and drugs associated with drug-induced immune hemolytic anemia - a new paradigm // Transfusion. 2007. Vol. 47(4). P. 697-702.
Joybari A.Y. et al. Oxaliplatin-induced renal tubular vacuolization // Ann. Pharmacother. 2014. Vol. 48(6). P. 796-800.
Kannan R., Laboyka R., Low P.S. Isolation and characterization of the hemichrome-stabilized membrane protein aggregates from sickle erythrocytes. Major sites of autologous antibody binding // J. Biol. Chem. 1988. Vol. 263 (27). P. 13766-13773.
Moreira-Rodrigues M. et al. Cardiac dysfunction in HgCl2-induced nephrotic syndrome // Exp. Biol. Med. (Maywood). 2010. Vol. 235 (3). P. 392-400.
Williams Hematology / Kaushansky K. et al. 8th Ed. 2010. P. 777-799.
References
Baier J.E., Poehlau D. Is alpha-methyldopa-type autoimmune hemolytic anemia mediated by inter-feron-gamma? Annals of Hematology. 1994, Nov; 69(5): 249-51.
Baker H.J., Lindsey J.R., Weisbroth S.H. The Laboratory Rat, Volume I: Biology and Disease. New York: Academic Press; 1979: 55-57.
Berger J. Phenylhydrazine haematotoxicity. J Appl Biomed. 2007; 5: 125-30.
Betensky M., Witmer C., Fisher M.J., Nance S., Weiss M.J., Sesok-Pizzini D.A. Immune hemolytic anemia with drug-induced antibodies to carboplatin and vincristine in a pediatric patient with an optic pathway glioma. Transfusion. 2014; 54 (11): 2901-2905.
Bollotte A., Vial T., Bricca P., Bernard C., Broussolle C., Sève P. Drug-induced hemolytic anemia: A retrospective study of 10 cases. Rev Med Interne. 2014; 35(12): 779-89.
El-Ashmawy I.M., Gad S.B., Salama O.M. Grape seed extract prevents azathioprine toxicity in rats. Phytother Res. 2010; 24(11): 1710-1715.
Exon J.H., Mather G.G., Bussiere J.L., Olson D.P., Talcott P.A. Effects of subchronic exposure of rats to 2-methoxyethanol or 2-butoxyethanol: thymic atrophy and immunotoxicity. Fundam Appl Toxicol. 1991 May; 16 (4): 830-40.
Garratty G., Arndt P.A. An update on drug-induced immune hemolytic anemia. Immunohematology. 2007; 23(3): 105-19.
Garratty G. Drug-induced immune hemolytic anemia. ASH Education Book January. 2009; 1: 73-79.
Ghanayem B.I., Sanchez I.M., Matthews H.B. Development of tolerance to 2-butoxyethanol-induced hemolytic anemia and studies to elucidate the underlying mechanisms. Toxicol Appl Pharmacol. 1992 Feb; 112 (2): 198-206.
Ghanayem B.I., Sullivan C.A. Assessment of the haemolytic activity of 2-butoxyethanol and its major metabolite, butoxyacetic acid, in various mammals including humans. Hum Exp Toxicol. 1993 Jul; 12 (4): 305-11.
Haddad H., Mohammad F., Dai Q. Bendamustine-induced immune hemolytic anemia in a chronic lymphocytic leukemia patient: A case report and review of the literature. Hematol Oncol Stem Cell Ther. 2014 Dec; 7(4): 162-4.
Haley K.M., Russell Th.B., Boshkov L., Leger R.M., Garratty G., Recht M. et al. Fatal carboplatin-induced immune hemolytic anemia in a child with a brain tumor. J. Blood Med. 2014; 15(5): 55-8.
Hillman R.S., Ault K.A., Rinder H.M. Hematology in Clinical Practice, 4th Edition. 2005: 135-151.
Hematology: basic principles and practice / R. Hoffman et al. 5th ed. 2008: pp. 645-659.
Horn S., Bashan N., Gopas J. Phagocytosis of phenyl-hydrazine oxidized and G-6-PD-deficient red blood cells: the role of cell-bound immunoglobulins. Blood. 1991 Oct 1; 78 (7): 1818-25.
Johnson S.T., Fueger J.T., Gottschall J.L. One center's experience: the serology and drugs associated with drug-induced immune hemolytic anemia - a new paradigm. Transfusion. 2007; 47(4): 697-702.
Joybari A.Y., Sarbaz S., Azadeh P., Mirafsharieh S.A., Rahbari A., Farasatinasab M. et al. Ox-aliplatin-induced renal tubular vacuolization. Ann Pharmacother. 2014; 48(6): 796-800.
Kannan R., Laboyka R., Low P.S. Isolation and characterization of the hemichrome-stabilized membrane protein aggregates from sickle erythrocytes. Major sites of autologous antibody binding. J. Biol. Chem. 1988, 263 (27): 13766-73.
Moreira-Rodrigues M., Henriques-Coelho Т., Moura C., Vasques-Novoa F., Sampaio-Maia В., Pestana M. et al. Cardiac dysfunction in HgCl2-induced nephrotic syndrome. Exp. Biol. Med. (Maywood). 2010; 235 (3): 392-400.
Williams Hematology / Kaushansky K. et al. 8th Edition. 2010: 777-799.